Birchview Capital’s Biolase, Inc. BIOL Stock Holding History

Birchview Capital’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-16	Closed	-$83K	–	56
2018 Q3	$83K	Sell	16 -38	-70%	-$152K	0.05%	53
2018 Q2	$165K	Sell	54 -49	-48%	-$185K	0.11%	47
2018 Q1	$522K	Hold	103	–	–	0.34%	28
2017 Q4	$548K	Hold	103	–	–	0.32%	22
2017 Q3	$775K	Hold	103	–	–	0.4%	18
2017 Q2	$1.25M	Hold	103	–	–	0.66%	5
2017 Q1	$1.74M	Hold	103	–	–	0.97%	5
2016 Q4	$1.8M	Hold	103	–	–	1.11%	6
2016 Q3	$2.25M	Hold	103	–	–	1.31%	5
2016 Q2	$1.5M	Hold	103	–	–	1.09%	8
2016 Q1	$1.69M	Hold	103	–	–	1.2%	6
2015 Q4	$1.08M	Buy	103 +8	+8%	+$87.4K	0.62%	13
2015 Q3	$1.07M	Hold	95	–	–	0.69%	13
2015 Q2	$2.06M	Hold	95	–	–	1.09%	11
2015 Q1	$2.4M	Hold	95	–	–	1.26%	8
2014 Q4	$3.12M	Buy	+95	New	+$2.97M	1.81%	6

Other funds holding BIOL

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TMC

Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Teton Advisors Rye, New York $173M AUM 77.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Birchview Capital's BIOL Position: Q4 2018 in Review

Birchview Capital sold out of Biolase, Inc. (BIOL) in Q4 2018, closing a stake of 16 shares — an estimated $83K sold.

Birchview Capital first reported a position in BIOL in Q4 2014 and held it in 16 quarters. The position peaked at $3.12M in Q4 2014. 18 funds tracked by Wall St. Rank hold BIOL as of Q4 2018.

Birchview Capital reported no remaining Biolase, Inc. position as of Q4 2018 after selling out during the quarter.
Birchview Capital sold 16 Biolase, Inc. shares in Q4 2018, an estimated $83K.
Birchview Capital first reported a position in Biolase, Inc. in Q4 2014 and held it in 16 quarters.
Birchview Capital's Biolase, Inc. position peaked at $3.12M in Q4 2014.
18 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2018.

Based on Birchview Capital's 13F filing for Q4 2018, filed 6 Feb 2019.